The effects of intravesical chemoimmunotherapy with gemcitabine and bacillus Calmette-Guérin in superficial bladder cancer: A preliminary study

D. Y. Cho, Jae Hyun Bae, Du Geon Moon, Jun Cheon, Jeong Gu Lee, Je-Jong Kim, D. K. Yoon, Hong Seok Park

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

This prospective study investigated the long-term effects of intravesical chemoimmunotherapy with gemcitabine (GEM) and bacillus Calmette-Guérin (BCG; n = 36) versus BCG alone (n = 51) for the treatment of superficial bladder cancer. For the chemoimmunotherapy (GEM + BCG) group, GEM (1000 mg) was instilled immediately after transurethral resection of bladder tumour (TURBT) and again (2000 mg) 1 week later. From 2 to 7 weeks after TURBT, BCG was instilled into the bladder of all patients once weekly. The recurrence-free period of the GEM + BCG group (24.13 months) was significantly longer than that of the BCG monotherapy group (19.81 months). The overall recurrence rate was similar between the groups, although at 6 and 9 months post-TURBT, GEM + BCG produced a significantly lower rate of recurrence compared with BCG alone. This study suggests that intravesical chemoimmunotherapy with GEM + BCG is effective in reducing early tumour recurrence and in prolonging the recurrence-free period of superficial bladder cancer.

Original languageEnglish
Pages (from-to)1823-1830
Number of pages8
JournalJournal of International Medical Research
Volume37
Issue number6
DOIs
Publication statusPublished - 2009 Jan 1

    Fingerprint

Keywords

  • BCG
  • Gemcitabine
  • Intravesical chemoimmunotherapy
  • Recurrence rate
  • Superficial bladder cancer

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Cite this